FENopta

Treatment tested

• Fenebrutinib

  Tyrosine-protein kinase BTK inhibitor

Placebo or sham

• Placebo

Other measures (12)

Inclusion Criteria: * A diagnosis of RMS in accordance with the revised 2017 McDonald Criteria. * Expanded Disability Status Scale (EDSS) score of 0 - 5.5 at screening. * For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs. * For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm. Exclusion Criteria: * Disease duration of > 10 years from the onset of symptoms and an EDSS score at screening \< 2.0. * Female participants who are pregnant or breastfeeding, or intending to become pregnant. * Male participants who intend to father a child during the study. * A diagnosis of Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (SPMS). * Any known or suspected active infection at screening, including but not limited to a positive screening tests for Hepatitis B and C, an active or latent or inadequately treated infection with tuberculosis (TB), a confirmed or suspected progressive multifocal leukoencephalopathy (PML). * History of cancer including hematologic malignancy and solid tumors within 10 years of screening. * Presence of other neurological disorders that could interfere with the diagnosis of MS or with the assessments of safety or efficacy during the study. * Clinically significant cardiovascular, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal disease. * Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study. * History of alcohol or other drug abuse within 12 months prior to screening. * History of or currently active primary or secondary (non-drug-related) immunodeficiency, including known history of human immunodeficiency virus (HIV) infection. * Inability to complete an MRI scan. * Adrenocorticotropic hormone or systemic corticosteroid therapy within 4 weeks prior to screening. * Receipt of a live-attenuated vaccine within 6 weeks prior to randomization. * Any previous treatment with immunomodulatory or immunosuppressive medication without an appropriate washout period.

This is a study evaluating the effect of fenebrutinib on brain magnetic resonance imaging (MRI) in participants with RMS. The safety and pharmacokinetics of fenebrutinib will also be evaluated. Participants will be randomized to receive either fenebrutinib or placebo. This study consists of two parts: Double-blind treatment (DBT) phase and an optional Open-label extension (OLE) phase.